Oct 23 (Reuters) - Medical equipment maker West

Pharmaceutical raised its annual profit forecast on

Thursday, after posting better-than-expected results for the

third quarter, banking on strong demand for its components used

in GLP-1 weight-loss and diabetes drugs.

The company's drug components business, which accounts for

47% of total revenue, benefited from higher demand during the

reported quarter as manufacturers sought critical packaging and

delivery components used throughout the injectable drug

production process.

West makes vital medical components - including stoppers,

plungers and delivery systems - to ensure the safe containment

and administration of injectable medicines such as vaccines and

biologic therapies.

The company's most notable customers include pharma majors

Eli Lilly ( LLY ) and Novo Nordisk, who incorporate

West's components into their blockbuster injectable treatments,

particularly in weight-loss and diabetes therapies.

The company previously flagged a $15 million to $20 million

impact from tariffs and said it is deploying every possible

lever to mitigate it.

West's third-quarter sales rose 7.7% to $804.6 million from

a year ago, beating analysts' average estimate of $787.9

million, according to data compiled by LSEG.

The company posted quarterly profit of $1.96 per share on an

adjusted basis for the quarter ended September 30, above

expectations of $1.68 apiece.

West Pharma expects 2025 adjusted profit between $7.06 and

$7.11 per share, up from a prior view of $6.65 and $6.85 per

share.

It also raised its annual sales forecast to a range of $3.06

billion to $3.07 billion, from a prior forecast of $3.04 billion

to $3.06 billion.